Cardioprotective Effects of Cardiopeptides for Injection in Patients With Non-severe Cardiac Disease: a Single-center Randomized Controlled Trial

Nanfang Hospital, Southern Medical University

Status and phase: Enrolling; Phase 4

Conditions: ICU; Myocardial Injury

Treatments: Drug: Cardiopeptides

Study type: Interventional

Funder types: Other

Identifiers

NCT06117046

NFEC-2023-060

Details and patient eligibility

About

The study was a single-center, randomized controlled trial. To explore the cardioprotective effect of cardiopeptide on non-heart disease patients with severe cardiac injury by comparing whether cardiopeptide was used.

Enrollment: 234 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥18 years old
2. The high-sensitive troponin T index was higher than the normal value during ICU hospitalization
3. Obtain the informed consent of the subject or legal agent

Exclusion criteria

1. Patients who are expected to die within 48 hours of ICU admission
2. previous diagnosis of acute coronary syndrome, chronic cardiomyopathy, pulmonary heart disease, acute myocarditis, pericardial tamponade and other diseases that have been confirmed to cause myocardial injury
3. cardiopulmonary resuscitation and/or electrical defibrillation before admission
4. patients with acute ischemic stroke
5. patients with stage 5 chronic kidney disease
6. during pregnancy or breastfeeding

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

234 participants in 2 patient groups

Cardiopeptides

Experimental group

Description:

Cardiopeptide was administered intravenously once a day with 60mg of cardiopeptide for 3 days

Treatment:

Drug: Cardiopeptides

Empety

No Intervention group